<DOC>
	<DOCNO>NCT00184730</DOCNO>
	<brief_summary>This trial conduct Japan . This protocol describe extension trial supply hGH subject wish continuous treatment long-term Phase 3 trial ( GHLiquid-1519 ) hGH product approve GHDA Japan .</brief_summary>
	<brief_title>Long-term Trial Growth Hormone Deficiency Adults ( GHDA )</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>Subjects complete GHLiquid1519 . If subject history treatment tumor pituitary peripheral site , two year pass since completion surgery , radiotherapy treatment , recurrence underlying disease exclude . Appropriate replacement therapy administer 24 week treatment pituitary hormone deficiency . Subject history acromegaly . Subject diabetes mellitus . Subject suffer malignancy . Several medical condition</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>